TITLE

A rare case of non-immune hemolytic anemia in a patient with metastatic breast cancer treated with capecitabine

AUTHOR(S)
Shaaban, Hamid; Downs, Erin; Shakouri, Payam; Guron, Gunwant
PUB. DATE
March 2013
SOURCE
Medical Oncology;Mar2013, Vol. 30 Issue 1, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Letter
ABSTRACT
The article describes the case of a 70-year-old African American woman with metastatic breast cancer diagnosed with non-immune hemolytic anemia. It provides a medical history of the patient. It explains the causal relationship observed between the palliative chemotherapy with oral capecitabine and the appearance of hemolytic anemia. It discusses the possibility of drug-induced hemolytic anemia in patients undergoing chemotherapy.
ACCESSION #
85859786

 

Related Articles

  • Haemolytic anaemia: case report.  // Reactions Weekly;5/15/2004, Issue 1001, p12 

    Discusses research being done on the occurrence of oxaliplatin-induced haemolytic anaemia in a female patient with metastatic colorectal cancer. Reference to a study by R. Hehlmann and colleagues, published in the March 2004 issue of the "Cancer Chemotherapy and Pharmacology"; Medical history...

  • Bevacizumab/tinzaparin sodium.  // Reactions Weekly;11/8/2008, Issue 1227, p7 

    The article describes a case of a breast cancer patient who died of haemorrhage after developing haemoptysis during chemotherapy with bevacizumab and tinzaparin sodium for anticoagulation. The 33-year-old patient with metastatic breast cancer experienced haemoptysis after receiving bevacizumab...

  • Capecitabine/lapatinib.  // Reactions Weekly;11/7/2009, Issue 1277, p12 

    The article describes the case of a 57-year-old woman who experienced diarrhea while under capecitabine and lapatinib treatment regimen. The patient was diagnosed with breast cancer with skin, bone, lung, liver, spleen and abdomen metastases. After receiving capecitabine and lapatinib, the...

  • Rasburicase.  // Reactions Weekly;Dec2014, Vol. 1530 Issue 1, p178 

    An abstract of the article "Cyanosis in a male Nigerian infant with acute kidney injury: Questions/Answers," by J. Pansy and colleagues is presented.

  • News in brief ...  // Reactions Weekly;8/14/2004, Issue 1014, p5 

    Highlights two studies on adverse reactions to drug therapy. Frequency of hepatotoxicity during antineoplastic therapy in breast cancer patients; Association of higher-than-normal doses of Î’-agonists with deteriorating asthma.

  • Trastuzumab.  // Reactions Weekly;10/31/2009, Issue 1276, p29 

    The article presents case reports of patients who developed cardiomyopathy during treatment with trastuzumab for breast cancer. All patients, aged 27-56 years and had breast cancer, started receiving trastuzumab with an anthracycline and all of them also previously received radiotherapy. All of...

  • Concurrent vs Sequential Adjuvant Chemotherapy and Hormone Therapy in Breast Cancer: A Multicenter Randomized Phase III Trial. Bedognetti, Davide; Sertoli, Mario Roberto; Pronzato, Paolo; Del Mastro, Lucia; Venturini, Marco; Taveggia, Paola; Zanardi, Elisa; Siffredi, Guido; Pastorino, Simona; Queirolo, Paola; Gardin, Giovanni; Wang, Ena; Monzeglio, Clara; Boccardo, Francesco; Bruzzi, Paolo // JNCI: Journal of the National Cancer Institute;Oct2011, Vol. 103 Issue 20, p1529 

    Background The most appropriate timing of chemotherapy and hormone therapy administration is a critical issue in early breast cancer patients. The purpose of our study was to compare the efficacy of concurrent vs sequential administration of adjuvant chemotherapy and tamoxifen. Methods Women...

  • Antineoplastics.  // Reactions Weekly;2/11/2006, Issue 1088, p8 

    This article presents a case report involving a female patient who developed posterior leukoencephalopathy during antineoplastic therapy for non-Hodgkin's lymphoma. It provides a background on the medical history of the patient. It describes the symptoms presented by the patient. It offers...

  • leuprolide.  // Davis's Drug Guide for Nurses, 9th edition;2005, p604 

    Deals with the antineoplastic agent leuprolide. Indications; Pharmacokinetics; Adverse reactions and side effects.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics